112 related articles for article (PubMed ID: 21778304)
1. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition.
Zheng Z; Amran SI; Thompson PE; Jennings IG
Mol Pharmacol; 2011 Oct; 80(4):657-64. PubMed ID: 21778304
[TBL] [Abstract][Full Text] [Related]
2. Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.
Zheng Z; Amran SI; Zhu J; Schmidt-Kittler O; Kinzler KW; Vogelstein B; Shepherd PR; Thompson PE; Jennings IG
Biochem J; 2012 Jun; 444(3):529-35. PubMed ID: 22502592
[TBL] [Abstract][Full Text] [Related]
3. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors.
Zvelebil MJ; Waterfield MD; Shuttleworth SJ
Arch Biochem Biophys; 2008 Sep; 477(2):404-10. PubMed ID: 18647592
[TBL] [Abstract][Full Text] [Related]
5. Identification of key residues in the A-Raf kinase important for phosphoinositide lipid binding specificity.
Johnson LM; James KM; Chamberlain MD; Anderson DH
Biochemistry; 2005 Mar; 44(9):3432-40. PubMed ID: 15736953
[TBL] [Abstract][Full Text] [Related]
6. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
7. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
Chaussade C; Rewcastle GW; Kendall JD; Denny WA; Cho K; Grønning LM; Chong ML; Anagnostou SH; Jackson SP; Daniele N; Shepherd PR
Biochem J; 2007 Jun; 404(3):449-58. PubMed ID: 17362206
[TBL] [Abstract][Full Text] [Related]
8. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy.
Talekar M; Ganta S; Amiji M; Jamieson S; Kendall J; Denny WA; Garg S
Int J Pharm; 2013 Jun; 450(1-2):278-89. PubMed ID: 23632263
[TBL] [Abstract][Full Text] [Related]
9. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma.
Fuchikami K; Togame H; Sagara A; Satoh T; Gantner F; Bacon KB; Reinemer P
J Biomol Screen; 2002 Oct; 7(5):441-50. PubMed ID: 14599360
[TBL] [Abstract][Full Text] [Related]
10. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 3-kinase isoform-specific effects in airway mesenchymal cell function.
Moir LM; Trian T; Ge Q; Shepherd PR; Burgess JK; Oliver BG; Black JL
J Pharmacol Exp Ther; 2011 May; 337(2):557-66. PubMed ID: 21349933
[TBL] [Abstract][Full Text] [Related]
12. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation.
Rodriguez-Viciana P; Warne PH; Vanhaesebroeck B; Waterfield MD; Downward J
EMBO J; 1996 May; 15(10):2442-51. PubMed ID: 8665852
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
14. New molecular determinants controlling the accessibility of ouabain to its binding site in human Na,K-ATPase alpha isoforms.
Crambert G; Schaer D; Roy S; Geering K
Mol Pharmacol; 2004 Feb; 65(2):335-41. PubMed ID: 14742675
[TBL] [Abstract][Full Text] [Related]
15. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.
Gkeka P; Papafotika A; Christoforidis S; Cournia Z
J Phys Chem B; 2015 Jan; 119(3):1002-16. PubMed ID: 25299356
[TBL] [Abstract][Full Text] [Related]
16. Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.
Flanagan JU; Shepherd PR
Biochem Soc Trans; 2014 Feb; 42(1):120-4. PubMed ID: 24450638
[TBL] [Abstract][Full Text] [Related]
17. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
18. Gi-mediated translocation of GLUT4 is independent of p85/p110alpha and p110gamma phosphoinositide 3-kinases but might involve the activation of Akt kinase.
Wang L; Hayashi H; Kishi K; Huang L; Hagi A; Tamaoka K; Hawkins PT; Ebina Y
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):543-55. PubMed ID: 10642513
[TBL] [Abstract][Full Text] [Related]
19. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.
Goodfellow GH; Dupret JM; Grant DM
Biochem J; 2000 May; 348 Pt 1(Pt 1):159-66. PubMed ID: 10794727
[TBL] [Abstract][Full Text] [Related]
20. Role of amino-acid residue 95 in substrate specificity of phosphagen kinases.
Tanaka K; Suzuki T
FEBS Lett; 2004 Aug; 573(1-3):78-82. PubMed ID: 15327979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
